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SASPThemajor hallmark of cellular senescence is an irreversible cell cycle arrest and thus it is a potent tumor suppressor
mechanism. Genotoxic insults, e.g. oxidative stress, are important inducers of the senescent phenotype which is
characterized by an accumulation of senescence-associated heterochromatic foci (SAHF) and DNA segments with
chromatin alterations reinforcing senescence (DNA-SCARS). Interestingly, senescent cells secrete pro-
inﬂammatory factors and thus the condition has been called the senescence-associated secretory phenotype
(SASP). Emerging data has revealed that NF-κB signaling is the major signaling pathway which stimulates the ap-
pearance of SASP. It is known that DNA damage provokes NF-κB signaling via a variety of signaling complexes con-
taining NEMO protein, an NF-κB essential modiﬁer, as well as via the activation of signaling pathways of p38MAPK
and RIG-1, retinoic acid inducible gene-1. Genomic instability evoked by cellular stress triggers epigenetic changes,
e.g. release of HMGB1proteinswhich are also potent enhancers of inﬂammatory responses.Moreover, environmen-
tal stress and chronic inﬂammation can stimulate p38MAPK and ceramide signaling and induce cellular senescence
with pro-inﬂammatory responses. On the other hand, two cyclin-dependent kinase inhibitors, p16INK4a and
p14ARF, are effective inhibitors of NF-κB signaling. We will review in detail the signaling pathways which activate
NF-κB signaling and trigger SASP in senescent cells.
© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Contents
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Fifty years ago, Hayﬂick andMoorhead [1] demonstrated that human
diploid ﬁbroblasts have a limited replication capacity in cell culture, i.e.
exhausted cells are irreversibly growth arrested. Maximum replication
in vitro, provoked by telomere attrition, characterizes only one type of
cellular stress which can permanently arrest the cell cycle and induce
cellular phenotype called cellular senescence. Currently, it is known
that several stress-related insults, in particular those attacking DNA
and inducing double strand breaks, can induce cellular senescence
[2–4]. Moreover, strongmitogenic signals, e.g. mutant HRASV12, can trig-
ger a cell cycle arrest, called oncogene-induced senescence (OIS). The se-
nescent phenotype includes several common characteristics in addition
to irreversible cell cycle arrest, e.g. (i) ﬂat, enlarged, oftenmultinucleated
morphology, (ii) induction of senescence-associated β-galactosidase
(SA-β-gal) activity, (iii) appearance of senescence-associated hetero-
chromatic foci (SAHF) and DNA segments with chromatin alterations
reinforcing senescence (DNA-SCARS), (iv) activation of tumor suppres-
sor network, such as p16INK4a and p19ARF, and (v) secretion of pro-
inﬂammatory mediators. Currently, there is a debate about the role of
cellular senescence in organismal aging and in age-related diseases. Sev-
eral studies have revealed that senescent cells will accumulate into tis-
sues in vivo during the aging process and in many diseases and
pathological conditions [5–8]. Oxidative stress and chronic inﬂammation
can induce genotoxic injuries and trigger cellular senescence which sub-
sequently can aggravate the pathogenesis. In cancer, OIS is a cellular host
defense mechanism preventing uncontrolled proliferation of cells with
genomic injuries.
Recently, a considerable amount of research has focused on the
mechanisms inducing cellular senescence, particularly into the question
about why/how arrested cell cycle might be associated with a secretory,
generally pro-inﬂammatory phenotype. Genotoxic insults and the ap-
pearance of SAHF and DNA-SCARS indicate that DNA damage response
is the inducer of inﬂammatory reaction (Section 4.1).Moreover, environ-
mental stress involving activation of p38MAPK and ceramide signaling
can induce cellular senescence and stimulate inﬂammatory responses
(Sections 4.2 and 4.6). Genomic instability in cellular stress can trigger
epigenetic changes, e.g. via release of HMGB1 proteinswhich could stim-
ulate inﬂammatory responses (Section 4.5). Current studies have
revealed that the NF-κB signaling system, the master control switch of
innate immunity responses, is a crucial pathway in the induction of
SASP and inﬂammatory responses in cellular senescence [9–11].
Vaughan and Jat [12] have recently presented a perspective on this re-
search ﬁeld.Wewill review here in detail the potential inducers and sig-
naling pathways which activate NF-κB signaling and subsequently
trigger SASP in cellular senescence (Fig. 1).
2. SASP: senescence-associated secretory phenotype
Judith Campisi and her group were the ﬁrst to reveal that senescent
cells could promote tumorigenesis in neighboring premalignant cells[13,14]. In their landmark study in 2008, they demonstrated that senes-
cent cells, induced by genotoxic stress, secreted amyriad of factors asso-
ciatedwith inﬂammation and oncogenesis [15]. They called this cellular
state the senescence-associated secretory phenotype (SASP). Genotoxic
stress, provoked by exhaustive replication or ionizing radiation, in-
duced a similar type of SASP in normal human ﬁbroblasts and epithelial
cells as well as in irradiated epithelial tumor cells. Secreted factors in-
cluded interleukins and chemokines, e.g. IL-1α/β, IL-6, IL-8, MCP-2
and MIP-1α, growth factors, such as bFGF, EGF and VEGF, and several
matrix metalloproteinases and nitric oxide [16]. Kuilman et al. [17]
demonstrated that oncogene-induced senescence (OIS) is also linked
to inﬂammatory proﬁle. Moreover, they revealed that IL-6 has a crucial
role in the generation of OIS since its depletion abolished oncogene-
induced cellular senescence, i.e. it suppressed the appearance of pro-
inﬂammatory phenotype as well as the increase in SAHF formation
and p15INK4B expression. In contrast, in SASP of normal human ﬁbro-
blasts, cell surface-bound IL-1α and IL-1R were the critical signaling
proteins which maintained the up-regulation of IL-6/IL-8 cytokine se-
cretion [18]. IL-1α, but not IL-1β, was also a senescencemarker of endo-
thelial cells and vascular aging [19]. Acosta et al. [20] demonstrated that
chemokine signaling via the CXCR2 receptors enhanced both replicative
senescence and OIS of human ﬁbroblasts. It seems that there are basic
physiological differences between SASP and OIS. Orjalo et al. [18] ob-
served that the secretome of normal ﬁbroblast SASP could promote
the invasive capabilities of cancer cells whereas Kuilman et al. [17]
reported that secretedmolecules of OIS clearly inhibited cancer cell pro-
liferation, probably supporting the senescence of nearby cancer cells by
paracrine fashion. These results imply that the secretory characteristics
of SASP are dependent on cell type and cellular context, e.g. type of cell
stress, its level and duration. The signaling regulation of cellular se-
nescence needs to be clariﬁed more thoroughly. It seems that there
are several positive, cell type speciﬁc feedback loops driven by secreted
inﬂammatory mediators which can boost autocrine senescence via the
transcriptional regulation, both in SASP and OIS. For instance, Bhaumik
et al. [21] observed that a robust SASP induced by IL-1α signaling stim-
ulated a delayed expression ofmiR-146a/b, an inhibitor of IRAK1mRNA,
which markedly down-regulated the secretion of IL-6 and IL-8. This in-
dicates that there are negative feedback loops against the inﬂammatory
SASP, e.g. via expression of miRNAs.
The biological role of cellular senescence as well as the functions
of SASP are still under debate [3,22–24]. It seems that senescent
cells protect themselves from converting to cancerous growth by
switching on SASP. Many of the secreted compounds are communica-
tive and they have autocrine and paracrine effects in tissue microen-
vironment but also at the systemic level. Some of the pro-
inﬂammatory cytokines and chemokines can arrest cell growth, e.g.
TGF-β (Section 4.4), but in general, inﬂammation enhances tumori-
genesis [25]. Moreover, inﬂammatory cytokines stimulate NF-κB sig-
naling in senescent cells and autonomously can prevent apoptosis
and thus maintain their senescent phenotype. Several studies have
conﬁrmed that apoptosis is reduced in senescent cells [26,27]. Many
Fig. 1. A general overview on the potential signaling pathways which can control the activity of IKK and NF-κB complexes and subsequently the induction of SASP. Genotoxic stress
stimulates NF-κB signaling via different pathways including the NEMO shuttle and both p38MAPK and RIG-1pathways. Environmental stress (without DNA damage) activates the
p38MAPK pathway and ceramide production. Inﬂammatory components activate the IKK complex via signaling pathways involving complexes assembled by TRAFs and TAK1.
HMGB1 can enhance inﬂammatory responses both in nuclei and after secretion. p16INK4a and p14ARF proteins are direct inhibitors of NF-κB signaling. Abbreviations: ATM, Ataxia
Telangiectasia Mutated; C/EBPβ, CCAAT/enhancer binding protein β; ELKS, a protein rich in glutamic acid, leucine, lysine and serine; HMGB1, high mobility group box protein 1;
IKKα/β, IκB kinase α and β; IL-1β, interleukin-1β; IRF-1, interferon regulatory factor-1; LUBAC, linear ubiquitin chain assembly complex; p38MAPK, mitogen-activated protein ki-
nase; MAVS, mitochondrial antiviral-signaling protein; MSK1/2, mitogen- and stress-activated protein kinases 1 and 2; NEMO, NF-κB essential modiﬁer; NF-κB, nuclear factor-κB;
p14ARF, alternate reading frame product of p16INK4a; p16INK4a, cyclin-dependent kinase inhibitor 2A; PARP-1, poly(ADP-ribose) polymerase-1; PIDD, p53-induced protein with a
death domain; PKCζ, protein kinase Cζ; RIG-1, retinoic acid inducible gene-1; RIP1, receptor interacting protein 1; SASP, senescence-associated secretory phenotype; SIRT6, silent
information regulator 6; TAB, TAK1-binding protein; TAK1, TGFβ-activated kinase 1; TGFβ, transforming growth factor β; TMEM9B, transmembrane protein 9B; TNFα, tumor ne-
crosis factor α; TRAFs, TNF-receptor-associated factors; WIP1, protein phosphatase 2Cδ.
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trigger the clearance of both senescent and oncogene-damaged
tumor cells. Secreted metalloproteinases support both tissue repair
and tumor progression. However, chronic inﬂammation is detrimen-
tal in tissues and it is associated with many age-related diseases,
e.g. metabolic disorders and cardiovascular and neurodegenerative
diseases. The aging process itself also involves a low grade inﬂamma-
tion [28,29] but currently, the role of cellular senescence is still
unclear in the aging process.
3. NF-κB signaling is a major inducer of SASP
There has been intensive research examining the signaling mecha-
nisms regulating cellular senescence and SASP. It is now clear that
tumor suppressor proteins p53 and pRB are involved in the appearance
of cellular senescence [14,30]. Their role seems to be linked to the arrest
of cell cycle rather than the induction of inﬂammatory SASP. Several re-
search approaches have revealed that C/EBPβ and NF-κB transcription
factors are involved in the regulation of secretory component of cellular
senescence [17,18,20,31]. Both of these transcription factors have been
implicated in the regulation of cellular stress and inﬂammatory signals.
NF-κB signaling is themajor immune regulator both in adaptive and in-
nate immunity systems [32,33]. C/EBPβ is a potent transcriptional co-
regulator in inﬂammatory responses [34,35] but also in cell cycle regu-
lation, e.g. arresting cellular proliferation via the pRB/E2F complex [36].
There seems to be cooperation between NF-κB and C/EBPβ signaling in
inﬂammatory regulation. For instance, Cappello et al. [37] observed that
C/EBPβ stimulated the NF-κB-dependent signaling by down-regulating
the expression of IκB-α, an inhibitory κB component. NF-κB and C/EBPβ
havemany synergistic effects, e.g. in the induction of CRP expression via
the IL-1β-stimulated autocrine IL-6 loop [38,39] but in some instances,
C/EBPβ can also block NF-κB signaling and inﬂammation [40]. It seems
that C/EBPβ is a context-dependent regulator of inﬂammation, probablydue to its capacity to interact with several signalingmolecules and tran-
scription factors [41].
Three recently published articles using different research models
have convincingly demonstrated that it is the NF-κB signaling which
promotes the presence of SASP in cellular senescence [9–11]. Chien
et al. [9] observed that NF-κB signaling controlled the appearance of
SASP in a well-characterized H-RasV12-induced senescence model
with human IMR-90 skin ﬁbroblasts. They demonstrated that the
p65 subunit of NF-κB complex was more signiﬁcantly enriched into
the chromatin of senescent ﬁbroblasts as compared to that of young
counterparts. Immunohistochemistry revealed that p65 was accumu-
lating into the SAHF-positive nuclei. They also observed that p65 was
clearly phosphorylated on Ser536, a transactivating modiﬁcation,
which correlated with increased expression and secretion of inﬂam-
matory markers. Microarray proﬁling showed that p53 and NF-κB
controlled distinct transcriptional modules but were complementary
since the down-regulation of p65 was sufﬁcient to bypass the H-
RasV12-induced senescence in human ﬁbroblasts [9]. Rouvillain et al.
[11] demonstrated that stimulation of the p53–p21Cip1 pathway pre-
dominantly evoked to cellular senescence in human ﬁbroblasts. They
also observed that senescence was associated with a prominent SASP,
with IL-1α and IL-1β being the most highly up-regulated genes. Inter-
estingly, they observed that the cell cycle arrest provoked by serum
starvation induced similar inﬂammatory changes as oncogene-
induced SASP. Rouvillain et al. [11] also revealed that the inhibition
of NF-κB signaling could overcome the growth arrest induced by
p53–p21Cip1 signaling which implies that the NF-κB pathway had a
causative role in the induction of SASP.
4. Signaling pathways activating NF-κB system in SASP
The NF-κB system is an evolutionarily conserved signaling path-
way which can be triggered not only by immune activation but also
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cence and the aging process, such as oxidative and genotoxic stresses.
The activation of the NF-κB system is linked to several pattern recog-
nition receptor pathways, e.g. TLRs and inﬂammasomes, as well as
through signaling from many upstream kinase cascades via canonical
and non-canonical pathways [33,42–44]. IKKα/β and NIK are the
most important upstream kinases although several kinases can di-
rectly regulate the transcriptional capacity of NF-κB factors. IKKγ,
generally called NEMO, is an important regulatory component of the
IKK complex being linked upstream to genotoxic signals
(Section 4.1) and IL-1 and TNF receptor mediated signaling [45]. NF-
κB transcription factors contain both the Rel family proteins (RelA/
p65, c-Rel and RelB) and NF-κB components (p50/p105 and p52/
p100) which are dimerized with each other in the cytoplasm and
inhibited by binding to IκB proteins (IκBα, IκBβ, IκBγ, IκBδ, IκBε,
IκBζ and Bcl3). Activating kinases phosphorylate IκB proteins which
are released from the complex and then degraded in proteasomes.
Subsequently, the NF-κB complexes translocate into the nucleus and
transactivate the expression of special sets of target genes. In addition
to IκB proteins, several signaling pathways and negative feedback
loops can also inhibit NF-κB signaling through different mechanisms
at various levels of the signaling cascades [46–48]. We will review
here the putative mechanisms which activate NF-κB signaling and
trigger SASP in senescent cells (Fig. 1).
4.1. DNA damage provokes NF-κB activation via NEMO shuttle
DNA damage is the common denominator inducing cell cycle ar-
rest and cellular senescence associated with many chromatin
changes, such as the accumulation of SAHF and DNA-SCARS
[4,49,50]. DNA damage is also a potent trigger for oncogene-induced
senescence. Moreover, genomic stability is clearly impaired during
organismal aging [51]. Several studies have demonstrated that DNA
damage can stimulate a robust secretion of inﬂammatory mediators
and is a common research model in SASP studies [9,10,50,52]. Rodier
et al. [52] demonstrated that ATM kinase had a crucial role in the ini-
tiation of SASP in the DNA damage response. For example, the deple-
tion of ATM prevented the secretion of IL-6 after irradiation in human
ﬁbroblasts. The effect of ATR was less prominent although it could
also contribute to the SASP response. ATM and ATR are the key pro-
tein kinases initiating the host defense after DNA damage. Interest-
ingly, the cytokine response was not dependent on the activation of
p53 and pRB, two factors known to arrest proliferation. By proﬁling
the secreted proteins, Rodier et al. [52] reported that ATM signaling did
not regulate the entire SASP secretome although it was required for the
secretion of the twomajor inﬂammatory cytokines, e.g. IL-6 and IL-8. In-
terestingly, ATM stimulation is known to trigger several downstream
pathways, e.g. via the control of NEMO activation and p38MAPK path-
ways (Section 4.2) which are involved in the inﬂammatory responses.
NEMO protein is the regulatory subunit of the IKK complex and
thus an essential modiﬁer of NF-κB signaling [45,53]. In addition to
IKK components, NEMO can interact with several other proteins asso-
ciated with NF-κB signaling, e.g. ATM, ELKS, RIP1 and TAK1. Post-
translational modiﬁcations, e.g. phosphorylation, sumoylation and
ubiquitination, control the binding targets and the function of
NEMO. It is recognized that DNA damage stimulates NF-κB signaling
which consequently regulates several host defense functions related
to cellular senescence, e.g. it induces resistance against apoptosis
and triggers innate immunity responses. Recent studies have revealed
that NEMO protein has a major role in the activation process of NF-κB
signaling evoked by DNA damage. Miyamoto [54] has recently de-
scribed in detail the signaling pathway driven by ATM and NEMO pro-
teins. We have termed this cascade as the NEMO shuttle since NEMO
protein is being transported between cytoplasm and nucleus [55].
Genotoxic stress, e.g. induced by oxidative stress, can trigger the
RIP1-mediated assembly of the complex between NEMO, PIDD andRIP1. PIDD is a p53-inducible protein and it is able to sensitize cells
to genotoxic stress [56]. Consequently, this tripartite complex trans-
locates into the nucleus where PIASy, a SUMO-1 ligase, sumoylates
NEMO protein. Subsequently, activated ATM phosphorylates NEMO
protein at Ser 85 which triggers desumoylation and facilitates its
monoubiquitination at Lys277 and Lys309. This modiﬁcation pro-
vokes the export of the ATM/NEMO complex into the cytoplasm
where it binds to the IKKs and ELKS, a scaffold protein of IKKs. The
ATM/NEMO complex activates the IKKα/β complex which triggers
NF-κB signaling by phosphorylating inhibitory IκB proteins.
There are several speciﬁc modiﬁcation steps which are linked to
the NEMO shuttle. For instance, Stilmann et al. [57] observed that ac-
tivated PARP-1, a sensor of DNA damage, could interact with NEMO
and this clearly enhanced the formation of nuclear complex between
ATM, NEMO and PIASy and promoted the sumoylation of NEMO. It is
known that PARP-1 can activate NF-κB signaling but its functional
role in the NEMO shuttle needs to be clariﬁed. The ectopic expression
of human PARP-1 in mice generated several age-related inﬂammatory
pathologies and neoplastic lesions; this implies that PARP-1 can en-
hance NF-κB signaling [58]. In addition, the ATM/NEMO complex
can be linearly ubiquitinated by LUBAC into the NEMO protein in cy-
toplasm [59]. Subsequently, that complex activates the TAK1 and IKK
complex. Moreover, ATM/NEMO can enhance the ubiquitination of
ELKS by XIAP which induces the binding of ELKS to TAK1 and activa-
tion of IKK complex and thus NF-κB signaling [60]. Recently, several
studies have revealed that cytoplasmic ATM, activated by DNA damage,
can also activate the IKK complex without NEMO, e.g. via the ATM/
TRAF6/cIAP1 module which stimulates TAK1-dependent activation of
IKK complex [61]. The ATM/NEMO/RIP1 complex can recruit TAK1
which activates IKKβ [62]. Interestingly, this TAK1 complex can activate
also p38MAPK which stimulates cell cycle arrest. TAK1 is the TGFβ1-
activated protein kinase and because TGFβ signaling has a crucial role
in cellular senescence, we will discuss later the functions of TGFβ and
TAK1 in Section 4.4.
Recently, Biton and Ashkenazi [63] revealed a TNF-α-dependent,
autocrine feedforward signaling loop triggered by ATM/NEMO activa-
tion in persistent DNA damage. The ATM-induced ubiquitination of
NEMO activates RIP1which is a crucial step in the cytokine, in particular
in the TNF-α-induced signaling pathway. In the DNA damage-induced
SASP, this so-called second wave, cytokine-mediated pro-
inﬂammatory response is augmented because the activation of RIP1
by ATM/NEMO potentiates the stimulation of JNK3 signaling through
TNF-α receptor. JNK3 enhances the expression and secretion of inﬂam-
matory proteins via the AP-1 factors and enhances the secretion inﬂam-
matory components in SASP. In conclusion, the ATM-induced NEMO
shuttle triggers NF-κB signaling which is controlled by its associations
with PARP-1, XIAP, RIP1 and TAK1.
4.2. Stress responses induce p38MAPK-dependent NF-κB activation
Mammalian p38 mitogen-activated protein kinase (p38MAPK) is
the signaling target of a wide variety of cellular stresses, e.g. oxida-
tive, metabolic and endoplasmic stresses, DNA damage, heat shock
and mechanical damage [64–66]. In addition, cytokines and other in-
ﬂammatory mediators activate the p38MAPK signaling pathway and
p38MAPKα has a crucial role in the inﬂammatory responses, in par-
ticular in the regulation of chemotaxis by enhancing the expression
of several chemokines, e.g. MIP-1α/β, MCP-1 and CCL5 [67]. Current-
ly, the kinases of p38MAPK pathway are potential drug discovery tar-
gets. An abundant literature indicates that p38MAPK is an important
inducer of cellular senescence triggered by either DNA damage or en-
vironmental stress [68–70]. It seems that p38MAPK can activate both
p53 and pRB-mediated arrest of cell proliferation, e.g. in Ras-induced
premature senescence [69]. Oxidative stress activates the MKK3/6-
p38 pathway and induces cellular senescence. Interestingly, Davis et
al. [71] demonstrated that an inhibitor of p38MAPK, SB203580,
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blasts and increase their replication capacity to that within the nor-
mal range. Werner syndrome is a segmental progeroid syndrome
where also cultured ﬁbroblasts reveal an accelerated replicative se-
nescence. SB203580 as well as many other p38 inhibitors is a potent
suppressor of cytokine expression and secretion [72] and this implies
that NF-κB signaling is involved.
Recently, Freund et al. [73] demonstrated that a constitutive
p38MAPKα activity could induce SASP in human ﬁbroblasts. The activa-
tion of p38MAPKα did not cause DNAdamage or activate ATMand CHK2
indicating that p38MAPKα was able to trigger SASP without genotoxic
stress. Interestingly, they observed that p38MAPKα controlled SASP via
the transcriptional activation of NF-κB signaling. Depletion of RelA/p65
signiﬁcantly reduced the secretion of pro-inﬂammatory cytokines in-
duced by p38MAPK activity. Moreover, p53 expression repressed the
p38MAPK activity which indicates that p53 can suppress the stimulation
of p38MAPK pathways and provide time for DNA repair. Furthermore, it
is known that p53 can inhibit NF-κB signaling via the activation of WIP1
[74]. WIP1 is a p53-inducible p38MAPK phosphatase which can also in-
hibit the signaling of ATM, CHK2, p53 and p38MAPK [75]. Zhang et al.
[76] demonstrated that the knockdown of WIP1 induced premature se-
nescence in human ﬁbroblasts. Chew et al. [77] observed that WIP1
was a negative regulator of NF-κB signaling which implies that
p38MAPK stimulates NF-κB signaling and subsequently induces SASP.
Many observations indicate that p38MAPK can stimulate NF-κB
signaling and inﬂammation through diverse mechanisms [67]. It is
well known that p38MAPK activates mitogen- and stress-activated
protein kinases, MSK1 and MSK2, which can phosphorylate the trans-
activating p65 subunit of the NF-κB complex at Ser276 and thus po-
tentiate NF-κB signaling [78–80]. For instance, oxidative stress
activates this same pathway [79]. MSK1/2 can also stimulate CREB
and STAT3 transcription factors which enhance inﬂammatory reac-
tions [80]. In UV radiation, CK2 kinase activates MSK2, but not
MSK1, in a p38MAPK-dependent manner and subsequently, MSK2
phosphorylates p65 protein at Ser276 and triggers NF-κB signaling
[81]. In 2002, Saccani et al. [82] demonstrated that p38MAPK can trig-
ger the phosphorylation of histone H3which induces promoter remo-
deling and in that way enhances the recruitment of NF-κB complexes
to certain promoters. Interestingly, they observed that the phosphor-
ylation was targeted selectively to the promoters of a subset of cyto-
kine and chemokine genes. The p38MAPK-activated genes included
IL-6, IL-8 and MCP-1 in human dendritic cells. Recently, Drobic et al.
[83] described that MSK1/2 provoked nucleosomal H3 phosphoryla-
tion at Ser10 and 28 which was coupled with the binding of the mul-
tiprotein chromatin remodeler complex involving 14–3–3 protein
and proteins of SWI/SNF complex. This complex was located at the
promoters which were engaged by NF-κB and AP-1 binding com-
plexes, well-known transactivators of inﬂammatory genes. The
p38MAPK-induced phosphorylation of H3, observed by Saccani et al.
[82], was probably mediated through MSK signaling. These observa-
tions indicate that the p38MAPK/MSKpathway triggers inﬂammatory re-
sponses targeting speciﬁcally those genes containing NF-κB factors. Saha
et al. [84] observed that the activation of p38MAPK induced the acetyla-
tion of p65 protein at Lys310, probably after the H3 phosphorylation. It is
known that the acetylation of p65 at Lys310 remarkably increases the
transactivation capacity of the NF-κB complex and subsequently pro-
vokes inﬂammatory responses [85]. In addition, p38MAPK signaling can
also stabilize the mRNAs of inﬂammatory mediators via the activation
of downstreamkinases, e.g. MAPKAPK2 [72]. All these observations indi-
cate that p38MAPK activation is a potent inducer of SASP associatedwith
cellular stress and probably with organismal aging.
4.3. Inﬂammasomal RIG-1 activates NF-κB signaling pathway
Inﬂammasomes are intracellular danger recognition complexes
which consist of the receptor protein as a sensor and several associatedproteins which trigger pro-inﬂammatory responses, including IL-1β
and IL-18 secretion [86]. Pathogens and cellular stress, e.g. oxidative
stress, potassium efﬂux and lipid accumulation, can provoke inﬂamma-
somal signaling. Recently, Liu et al. [87] demonstrated that the RIG-1
type of the inﬂammasome receptor was activated in cellular stress in-
duced by irradiation or replicative senescence in human ﬁbroblasts
and endothelial cells. These treatments induced a robust, RIG-1-
dependent secretion of IL-6 and IL-8. Cellular senescence also increased
the expression level of RIG-1. Moreover, the expression of RIG-1 was
clearly increased in various tissues taken from old mice. RIG-1, retinoic
acid inducible gene-1, is a speciﬁc viral recognition system although re-
cent studies have conﬁrmed that it can also possess other functions e.g.
in inﬂammation, cancer, apoptosis and senescence [88,89]. There are
several upstream and downstream pathways which are linked to the
activation and signaling of RIG-1. Liu et al. [87] demonstrated that gen-
otoxic stress activated the ATM-IRF1 axis since knockdown of ATMpre-
vented both the induction of RIG-1 and IL-6 expression. Downstream
RIG-1 signaling can be linked via ASC to the caspase-1-induced IL-1β
production or viamitochondrial MAVS adapter protein to NF-κB signal-
ing [89]. Liu et al. [87] observed that silencing of MAVS, aswell as RIG-1,
clearly suppressed the IL-6 expression in senescent cells. MAVS protein
can also be linked downstream to IRF3 activation and IFN-β production.
Liu et al. [87] demonstrated that IRF3/IFN-β pathway was not activated
in cellular senescence. It seems that genotoxic stress and replicative se-
nescence activate the NF-κB system and IL-6 and IL-8 expression via the
ATM/MAVS pathway. However, Liu et al. [87] did not report whether
the caspase-1-mediated pathway was activated. Interestingly, knock-
down of RIG-1 in senescent HUVEC cells led to the extension of their
lifespan [87] which suggests that RIG-1-induced inﬂammatory re-
sponse can aggravate cellular senescence and organismal aging.
Next, Liu et al. [87] demonstrated that Klotho protein can inhibit
the RIG-1-induced activation of NF-κB signaling and IL-6 production
in cellular senescence. Klotho is a well-known anti-aging protein,
i.e. its deletion accelerates the aging process whereas overexpression
extends the lifespan of mice [90]. It is also known that Klotho can in-
hibit NF-κB signaling and prevent endothelial inﬂammatory re-
sponses [91]. Liu et al. [87] observed that the intracellular, but not
the secreted form, clearly suppressed the RIG-1-mediated NF-κB acti-
vation and IL-6 expression. They also revealed that Klotho directly
interacted with the CARD domain of RIG-1 protein and in that way
could prevent the binding of downstream signaling molecules to the
CARD motif. This observation suggests that the intracellular isoform
of Klotho could also inhibit other inﬂammasomal pathways.
4.4. TGF-β–TAK1 pathway stimulates NF-κB signaling
The transforming growth factor-β (TGF-β) family of cytokines
controls a diversity of homeostatic cellular functions, e.g. prolifera-
tion, differentiation, apoptosis and immune responses via a complex
signaling network [92–94]. Most of the signaling connections are me-
diated via SMAD factors but recently many non-SMAD pathways have
been revealed, e.g. the TRAF6–TAK1–p38MAPK signaling and many
connections of TAK1 to the activation of IKK–NF-κB pathway
[94–96]. TGF-β signaling is a potent inhibitor of proliferation e.g. in
epithelial, endothelial and myeloid cells whereas it is mitogenic for
many mesenchymal cells [97]. TGF-β stimulates the expression of
Cdk inhibitors including p15, p19, p21 and p27 and it induces growth
arrest and cellular senescence e.g. in mouse keratinocytes, human ﬁ-
broblasts and hepatocellular carcinoma cells [98–100]. Several stud-
ies have demonstrated that TGF-β can trigger the expression and
secretion of IL-8 in many cancer cells [101,102]. Moreover, TGF-β sig-
naling increased with aging in the brain [103] and chronic astrocytic
overproduction of TGF-β1 has promoted Alzheimer's disease-like mi-
crovascular degeneration in transgenic mice [104]. In Caenorhabditis
elegans, the secretion of DAF-7, an orthologue of mammalian TGF-β,
by chemosensory neurons induced the formation of dauer larva, a
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tions [105].
Oxidative stress stimulates TGF-β expression and subsequently
triggers cellular senescence e.g. in human ﬁbroblasts [106] and reti-
nal pigment epithelial cells [107]. In both cases, treatment with neu-
tralizing antibodies against the TGF-β isoforms and TGF-RII receptors
prevented the oxidative stress-induced increase in senescence-
associated biomarkers. The TGF-β1 signaling pathway was also in-
volved in the UVB-induced premature senescence in human ﬁbroblasts
[108]. Ionizing radiation, probably via DNA damage, also stimulated the
expression of TGF-β and its receptors [109–111]. The upstreammecha-
nisms still need to be clariﬁed to explain the increased TGF-β expression
in cellular senescence. Abraham et al. [112] demonstrated that the
promoter of TGF-β1 contains a functional binding site for the
CCAAT/enhancer binding protein β (C/EBPβ) which enhanced the
expression of TGF-β1. Interestingly, they observed that the p65 com-
ponent of NF-κB could bind to C/EBPβ protein and repress TGF-β1 ex-
pression. Functional CCAAT boxes have been described in the
promoters of TGF-β receptor genes, those of type I, II and III receptors
[113–115]. Gomis et al. [116] observed that the cytostatic effect of
TGF-β was inhibited by the expression of LIP, a C/EBPβ inhibitory iso-
form. These observations clearly indicate that C/EBPβ has a crucial
role in the expression of TGF-β. The transcription factor C/EBPβ carries
outmany fundamental actions e.g. in energymetabolism, innate immu-
nity, inﬂammation, cell proliferation and senescence [117,118]. Cur-
rently, it seems that C/EBPβ is strictly epigenetically regulated by
arginine methyltransferase 4 (PRMT4) and interactions with remodel-
ing complex SWI/SNF [119]. Kuilman et al. [17] and Orjalo et al. [18]
demonstrated that C/EBPβ is an important regulator of IL-6 expression
and inducer of SASP. Recently, Atwood and Sealy [120] demonstrated
that Ras(V12)-triggered oncogene-induced senescence was mediated
by the C/EBPβ1 isoform which also up-regulated the expression of IL-
6 in normal ﬁbroblasts.
The SMAD transcription factors involve the major signaling path-
way downstream from the TGFβ receptors [93]. However, TGFβ re-
ceptors can also activate signaling via three non-SMAD pathways,
i.e. TAK1, RhoA and PI3K-mediated signaling [94,96]. It is known
that TAK1, a TGFβ-activated protein kinase 1, has a crucial role in
the activation of NF-κB signaling and inﬂammatory responses
[121–123]. Recent studies have revealed that TAK1 is not only linked
to TGFβ signaling but can also regulate NF-κB activation stimulated
by IL-1β and TNFα [96,124]. The key event in the activation of TAK1
is its Lys-63-dependent polyubiquitination at Lys-34 which is trig-
gered by TRAF6 or TRAF2/5. Subsequently, TAK1 interacts with
TAB1 protein and will be autoactivated by phosphorylation at Thr-
178, Thr-187 and Thr-184 in the TAK1 T-loop [125,126]. Autopho-
sphorylation of TAK1 is required for IL-1-mediated activation of
IKK–NF-κB and JNK-AP-1 signaling and expression of IL-6 [125]. On
the other hand, Mao et al. [127] demonstrated that in the TGFβ-
induced signaling pathway, TRAF6 targets ubiquitination to TAK1
Lys-158, not Lys-34 as in IL-1β and TNF-α signaling, and subsequent-
ly TAK1 can activate IKK, p38 and JNK pathways. TAK1 interacts with
the IKK complex which is a crucial step in the activation of NF-κB sig-
naling [121]. In order to acquire speciﬁcity, the TAK1 complex is asso-
ciated with TAB2, TAB3 and TAB4 adaptors which recruit other
modulators, e.g. RIP1, NEMO and MKK3/6, to facilitate distinct signal-
ing pathways [128,129]. TAK1 is also a client protein of Hsp90 which
is an important stability factor for the pro-inﬂammatory complexes
[130]. Currently, it is still unclear how the TAK1 complexes are tar-
geted to the correct signaling pathways.
Dodeler et al. [131] identiﬁed TMEM9B protein when they studied
the role of TAK1 and RIP1 in the signaling of TNFβ. TMEM9B is a gly-
cosylated transmembrane protein localized in lysosomes, particularly
in the membranes of early endosomes. The expression of TMEM9B
protein is required for the activation of NF-κB by TNF-α, IL-1β and
TLR ligands and subsequently for the induction of pro-inﬂammatoryresponse. They observed that TMEM9B acts in the signaling pathway
downstream of RIP1, likely at the level of TAK1, but in any case up-
stream of IKKα/β. Dodeler et al. [131] also demonstrated that
TMEM9B undergoes interactions with RIP1 and TAK1 and this leads
to stimulation of p38MAPK and JNK signaling (Section 4.2). Interest-
ingly, the TMEM9B protein is associated only with inﬂammatory re-
sponses, not with apoptosis. Recently, Rovillain et al. [132]
undertook senescence bypass screening to reveal that the TMEM9B
protein is a novel downstream effector of p53–p21Cip1 and
p16INK4a–pRB pathways in human ﬁbroblasts. Silencing of the ex-
pression of TMEM9B protein could overcome the senescence. Another
protein they identiﬁed was LTB2/3, a latent TGF-binding protein 2/3,
which has a major role in the activation of TGFβ signaling. The silenc-
ing of LTB2/3 also bypassed senescence conﬁrming a crucial role of
TGFβ signaling in cellular senescence. These observations clearly
demonstrate that NF-κB activation and inﬂammatory factors have a
fundamental role in the generation of SASP.
SIRT6, amember of mammalian Sirtuins, interacts with NF-κB in the
chromatin and controls the expression of NF-κB target genes [133,134].
SIRT6 associates with the p65 component of NF-κB, deacetylates his-
toneH3 Lys9 and thus inhibits the expression of NF-κB target genes. De-
pletion of SIRT6 induces the hyperacetylation of histones and increases
the expressionofNF-κB-dependent genes. The absence of SIRT6 induces
a progeroid degenerative disease in mice [135]. Minagawa et al. [136]
observed that SIRT6 could regulate the TGFβ-induced cellular senes-
cence in bronchial epithelial cells. Epithelial senescence in pulmonary
ﬁbrosis increased the expression of p21Cip1 and SA-β-gal as well as
the expression of SIRT6. In cell culture experiments, they observed
that TGFβ increased the expression of SIRT6 in a dose-dependent man-
ner. Overexpression of SIRT6 reduced the level of SA-β-gal staining
while SIRT6 siRNA dramatically increased the presence of SA-β-gal in
epithelial cells. They also observed that the increased expression of
SIRT6 suppressed the secretion of IL-1β. These results suggest that
SIRT6 antagonizes the cellular senescence induced by TGFβ. They also
indicate that SIRT6 can repress the transcription of NF-κB dependent
genes i.e. evidence that the inﬂammatory response is a driving force
in cellular senescence.
4.5. HMGB1 potentiates NF-κB signaling and inﬂammatory responses
The HMGB1 protein is included into the family of high mobility
group proteins which are chromatin-associated, non-histone proteins
controlling e.g. transcription, replication and DNA repair. Moreover,
HMGB1 is a secreted cytokine, an alerting danger signal, which re-
ports immune system from overwhelming cellular stress and it re-
cruits new immune cells into tissues [137–139]. Lamkanﬁ et al.
[140] demonstrated that inﬂammasomes, cellular danger recognizing
system, triggered the release of HMGB1 from jeopardized cells in
endotoxemia. The major characteristic of HMGB1 proteins is their ex-
tremely good capacity to interact with other proteins, e.g. transcrip-
tion factors, receptors, and cytokines. For instance, the binding of
HMGB1 with some cytokines, e.g. IL-1β and TNF-α, clearly potenti-
ates their inﬂammatory responses [141,142]. Secreted HMGB1 pro-
teins induce inﬂammatory signaling by binding and activating
several innate immunity receptors, e.g. RAGE, TLR2 and TLR4, which
are linked to the NF-κB pathway [139]. The expression of HMGB1 is
also up-regulated in several inﬂammatory diseases, such as athero-
sclerosis and ischemic injuries. Tang et al. [143] demonstrated that oxi-
dative stress triggered the translocation of HMGB1 from the nuclei to the
cytoplasm where it interacted with Beclin 1 and induced the autophagic
response which improved cell survival. These studies indicate that in cel-
lular stress, HMGB1 is released from the nuclei to facilitate cellular de-
fense and to alert the immune systemabout the estimated tissue damage.
One important function ofHMGBproteins is to assist transcription fac-
tors in gene expression [144]. HMGB1/2 proteins bind to histone H1 pro-
teins on the DNA linker region between nucleosomes. It seems that
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inhibitory effect of H1 proteins. HMGB1 is a so-called architectural factor
which enhances the DNA binding of transcriptional factors and stabilizes
the protein binding toDNA. Agresti et al. [145] demonstrated thatHMGB1
protein directly interactedwith the p50protein, theDNA-binding compo-
nent of the NF-κB complex, and enhanced the DNA-binding of p65/p50
andp50/p50 complexes but not otherNF-κB complexes. They also proved
that HMGB1 protein is required for the expression of inﬂammatory adhe-
sion protein VCAM-1. These observations conﬁrmed thatHMGB1 is a pro-
inﬂammatory cytokine which can also potentiate the transcriptional ac-
tivity ofNF-κB factors and thus the expressionof inﬂammatorymediators.
HMGB1 as well as HMGA2 is a chromatin protein which regulates
chromatin remodeling during cellular differentiation and senescence.
Narita et al. [146] observed that HMGA proteins accumulated into the
chromatin of senescent ﬁbroblasts, in particular to SAHF foci promot-
ing their formation by p16INK4a proteins. Recently, Celona et al. [147]
demonstrated that HMGB1 is a crucial protein in the nucleosome as-
sembly, i.e. depletion of HMGB1 reduced the quantity of core, linker
and variant histones and signiﬁcantly decreased nucleosome assem-
bly. This open-chromatin status increased the global gene transcrip-
tion and also changed speciﬁc transcriptomes. El Gassar et al. [148]
revealed that HMGB1 protein cooperated with nucleosomal H1 linker
protein in the control of TNF-α transcription. They observed that the
p65/RelA subunit of NF-κB was recruited to the promoter of TNF-α in
endotoxin-responsive cells whereas in the tolerant cells, the presence
of H1 linker protein employed HMGB1 and they formed a complex
with RelB, a repressor component of NF-κB signaling. This silencing
of TNF-α transcription was induced by the dimethylation of H3K9
and binding of the heterochromatin protein HP1 into the TNF-α pro-
moter. They also described a similar silencing system in the transcrip-
tion of IL-1β in the endotoxin tolerant cells. Interestingly, Funayama
et al. [149] observed that SAHF-positive, senescent human ﬁbroblasts
exhibited a deﬁciency in their linker histone H1 proteins. Different se-
nescence insults, such as p38MAPK stimulation, triggered the loss of
chromatin-bound H1 proteins. Their results also indicated that deple-
tion of H1 protein from chromatin was induced by posttranslational
regulation. It is known that histone H1 variants have a profound effect
on higher order structures in chromatin as well as in gene expression
[150]. In conclusion, these observations depict a scenario where per-
manent changes in chromatin structure during cellular senescence
evoke the transactivation of pro-inﬂammatory genes e.g. via
p38MAPK/MSK signaling (Section 4.2) and release of pro-
inﬂammatory HMGB1 proteins enhancing the formation of SASP. Re-
cently, Funayama and Ishikawa [49] have reviewed in detail the
structural changes observed in chromatin during cellular senescence.
4.6. Accumulation of ceramides triggers NF-κB activation
The senescent phenotype has a profound effect on cellular metabo-
lism which could subsequently trigger NF-κB signaling and induce
SASP. Oxidative stress is one way of provoking cellular senescence,
but another, more stable type of stress is that evoked by ceramides
[151,152]. Ceramides are lipid molecules composed of sphingosine
and fatty acid. Ceramides are present in cell membranes but they also
have important functions in cellular signaling [153,154]. Venable et al.
[151] demonstrated that the ceramide level was clearly increased in se-
nescent ﬁbroblasts andmoreover, ceramide treatment of ﬁbroblasts in-
duced cellular senescence involving the appearance of SA-β-gal [152].
Venable et al. [151] observed that the activity of neutral sphingomyeli-
nase was greatly increased in senescent cells. There is clear evidence
that activation of neutral sphingomyelinase 2 during aging increases
the concentration of ceramides and potentiates inﬂammatory re-
sponses, e.g. via IL-1β receptor [155,156]. Several stress insults can trig-
ger the accumulation of ceramides by affecting the sphingolipid
metabolism [157]. For instance, different types of environmental stress
such as genotoxic and oxidative stresses, many inﬂammatory cytokinesand cytotoxic compounds can increase the cellular ceramide level. On
the other hand, ceramide and in particular, its metabolite ceramide-1-
phosphate are multifunctional signaling molecules which can (i) acti-
vate several kinases, e.g. PKCζ, p38MAPK and JNK, (ii) activate protein
phosphatases, such as PP1 and PP2A, (iii) stimulate phospholipase A2
[153,154,158]. Sphingolipid metabolites, i.e. ceramides, its phosphate
and sphingosine 1-phosphate, can induce inﬂammatory responses and
thus they are involved in many inﬂammatory diseases [159,160].
Wang et al. [161] demonstrated that ceramide can directly acti-
vate protein kinase Cζ (PKCζ). They also observed that activation is
a concentration-dependent process, i.e. low concentrations activated
PKCζ and JNK whereas high concentrations inhibited PKCζ activity
by generating a complex between PKCζ and PAR-4, an inhibitor of
PKCζ. Several studies have demonstrated that PKCζ stimulates NF-
κB signaling by phosphorylating the RelA/p65 subunit [162] or IKKβ
[163] and thus activates NF-κB signaling. Chang et al. [164] observed
that the p62 adapter protein could form a ternary complex with PKCζ
and PAR-4. They also demonstrated that binding of p62 activated the
PKCζ/NF-κB signaling pathway. PKCζ is a multifunctional signaling
molecule which can undergo crosstalk with many signaling pathways
[165]. It is known that several cytokines, e.g. IL-1β and TNF-α, can ac-
tivate NF-κB signaling via the complex between TRAF6/p62/PKCζ
which then triggers IKKβ [166]. Furthermore, Bourbon et al. [167] ob-
served that the ceramide-induced activation of PKCζ inhibited Akt
signaling which subsequently arrested cell proliferation.
In addition to PKCζ signaling, sphingolipid metabolites can adjust
cellular stress responses via other pathways. For instance, ceramide
can stimulate ASK1/p38MAPK and JNK signaling by inducing the ex-
pression of TXNIP [158]. Ceramides can also activate C/EBP transcrip-
tion factor [168] and thus stimulate TGF-β signaling (Section 4.4).
Recently, Alvarez et al. [169] demonstrated that sphingosine 1-
phosphate activated TRAF2 which subsequently induced Lys63-
linked polyubiquitination of RIP1 and activation of IKKα/β and NF-
κB signaling. On the other hand, ceramides stimulate PP2A which in-
hibits NF-κB signaling by dephosphorylating upstream kinases and
directly RelA/p65 component and in that way it can counteract the
ceramide-induced pro-inﬂammatory responses [170,171]. In conclu-
sion, stress-activated ceramide signaling is a potent inducer of SASP
since for instance, ceramides are tumor suppressors and p53 regu-
lates sphingolipid metabolism [172].
5. Repression of NF-κB signaling by p16INK4a and p14ARF
There has been debate about whether SASP can enhance cellular
senescence or is SASP a separate entity appearing in senescent cells.
Coppe et al. [173] demonstrated convincingly that cellular senescence
can appear without SASP. Ectopic expression of p16INK4a, a cyclin-
dependent kinase inhibitor and a hallmark of cellular senescence,
did not stimulate the secretion of pro-inﬂammatory cytokines or in-
duce paracrine oncogenesis. Moreover, Coppe et al. [173] observed
that the induction of SASP after DNA damage was independent of
p16INK4a expression. Therefore, this study substantiated earlier ob-
servations that cell cycle arrest does not necessarily lead to SASP. In-
terestingly, Wolff and Naumann [174] demonstrated that p16INK4
was a potent inhibitor of NF-κB signaling, e.g. overexpression of
p16INK4 repressed the transactivation of the NF-κB system. The
INK4 family of proteins, including p16INK4a, p15INK4b, p18INK4c
and 19INK4d, contains ankyrin repeats which are binding domains
in RelA/p65 and IκB proteins [175]. Wolff and Naumann [174] ob-
served that p16INK4 and RelA/p65 interacted, in particular after
TNFα stimulation when RelA/p65 was released from IκB proteins
and was translocated into the nucleus. It seems that the lack of
SASP after p16INK4a overexpression [173] could be induced by the
suppression of NF-κB signaling by p16INK4 proteins.
Another INK box protein, p14ARF is an effective tumor suppressor
which can activate the p53/p21Cip1 pathway. Rocha et al. [176]
842 A. Salminen et al. / Cellular Signalling 24 (2012) 835–845demonstrated that the activation of p14ARF stimulated the phosphor-
ylation of RelA/p65 at Thr505 via the ATR/Chk1 kinase pathway. This
phosphorylation site is located in the transactivation domain of RelA/
p65 and its modiﬁcation induced a clear, p14ARF-dependent inhibi-
tion of NF-κB signaling. The activation of p14ARF could also activate
ATR/BRCA1 pathway in the nucleoli and induced the phosphorylation
of p53 at Ser15 which triggered cell cycle arrest and possibly leading
to apoptosis. Cheung et al. [177] have demonstrated that the collabo-
rator of p14ARF, so-called CARF, controlled cellular fate induced by
p14ARF/p53, i.e. homeostasis, senescence, cancer or apoptosis. There
is also close cooperation between p14ARF and TWIST, a multifunc-
tional basic helix–loop–helix transcription factor [178]. Kwok et al.
[178] demonstrated that overexpression of TWIST down-regulated
the expression level of p14ARF protein and simultaneously sup-
pressed cellular senescence in human epithelial cells. They also ob-
served that suppression of TWIST expression promoted cellular
senescence, e.g. the appearance of phosphorylated histone H2AX. In-
terestingly, Sosic et al. [179] observed that transgenic mice either ho-
mozygous for twist-2 null allele or heterozygous for twist-1 and -2
alleles expressed elevated level of pro-inﬂammatory cytokines TNF-
α, IL-1β and IL-6. They demonstrated that TWIST could bind to the pro-
moters of these cytokines and inhibit both the basal and inducible activity.
Moreover, they observed that TWIST and RelA/p65 could physically inter-
act and this interaction repressed speciﬁcally the RelA/p65-dependent ac-
tivation of cytokine genes. It seems that there is a negative feedback loop
since TNF-α activated TWIST expression whereas TWIST repressed cyto-
kine expression. It is not known whether SASP is associated with the
down-regulation of TWISTs.
In addition to p16INK4a and p14ARF, there are two other families
of mammalian G1 cyclin-dependent kinase inhibitors, p21Cip1 and
p27Kip1 [180]. p53, activated by DNA damage, can stimulate the ex-
pression of p21Cip1 which arrests the cell cycle in the G1 phase. In-
stead, the expression of p27Kip1 is induced by TGF-β [181]. The
activation of Ras stimulates the expression of both p21Cip1 and
p27Kip1. There are differences between the accumulation and func-
tion of p16INK4a and p21Cip1 proteins [182]. It seems that p21Cip1
is involved in the cell cycle arrest whereas p16INK4a may be essential
for the maintenance of the cell cycle arrest during cellular senescence.
p16INK4a accumulates later than p21Cip1 and its expression corre-
lates with the appearance of SA-β-gal and a ﬂat morphology. Interest-
ingly, in contrast to p16INK4a and p14ARF, it is known that p21Cip1
and p27Kip1 can increase the transcriptional activity of NF-κB
[174,183]. Coppe et al. [15] demonstrated that p53 repressed the ap-
pearance of SASP. This is in line with the observations that p53 and
NF-κB have antagonistic responses and p53 can inhibit, via WIP1 ac-
tivation, the p38MAPK-driven NF-κB activation (Section 4.2). It
seems that the p53/p21Cip1-induced activation of NF-κB is not likely
to be involved in the generation of SASP. In contrast, the TGF-β/
p27Kip1-enhanced transactivation of NF-κB may occur although the
TAK1-dependent pathway has been studied in greater detail
(Section 4.4). In conclusion, it should be emphasized that the cell
cycle arrest is not automatically linked to the cellular senescence pro-
gram, as discussed by Blagosklonny [184], but it requires an irrevers-
ible block of regulation which still needs to be clariﬁed, particularly
the role of NF-κB-driven appearance of SASP.
6. IKK-dependent but NF-κB-independent regulation
One key question in the regulation of SASP generation is whether
all roads lead to NF-κB activation. The secretory component of SASP
involves cytokines, chemokines, growth factors and metalloprotei-
nases, i.e. all of these are mostly inﬂammatory elements. NF-κB sig-
naling is the master regulator of inﬂammatory responses (Section 3)
and thus it seems that the NF-κB system is the principal mechanism
in the induction of SASP. The NF-κB system is an ancient signaling
pathway which issues alerts in response to a wide variety of insultsand cellular stress to facilitate innate immunity responses and to es-
tablish cellular defense in order to maintain homeostasis. The NF-κB
system integrates a complex signaling network in which secreted,
mostly communicative, inﬂammatory factors are only a part of the
repertoire of NF-κB responses [33,183]. Moreover, it should be
noted that most of the signaling pathways target the IKK complex
(Fig. 1), which means that IKKα and IKKβ can activate NF-κB-
independent targets, e.g. β-catenin, histone H3, TSC1, FOXO3a and
several nuclear co-activators. IKKα has a crucial role in epidermal
morphogenesis during development [185] and in the maintenance
of skin homeostasis [186]. Perkins [183] and Cariot [187] have recent-
ly reviewed in detail the targets of IKK proteins and their functions. In
addition, the NF-κB system participates in crosstalk with several tran-
scription factors which join together different signaling pathways, e.g.
JNK, p53 andWnt. For instance, cellular stress stimulates both the NF-
κB and p53 signaling pathways but actually, they trigger many antag-
onistic functions [74,188]. Currently, it is known that different signal-
ing pathways oscillate within a wide timescale, most likely also in the
generation of SASP and cellular senescence. Recently, Mengel et al.
[189] have reviewed the oscillatory control in NF-κB, p53 and Wnt
signaling.
Cellular senescence involves several morphological and energy
metabolic changes during the generation of the senescent phenotype.
It is known that NF-κB signaling can regulate energy homeostasis
[190,191] and the major housekeeping system, i.e. the autophagic
cleansing system [192,193]. Currently, there is a debate about the
role of autophagy in the generation of cellular senescence. Some stud-
ies have indicated that autophagy is an inducer of senescent pheno-
type [194–196] and others have reported that impairment of
autophagy triggers premature senescence [197]. Cellular stress in-
duces autophagocytosis, a self-eating process, which has many crucial
functions in cellular survival. Moreover, the autophagic degradation
capacity declines with aging in many tissues [198]. Recent studies
have demonstrated that p53 and p14ARF are crucial inducers of
autophagy e.g. in genotoxic stress [196]. These factors act mutually
as inhibitors of NF-κB signaling (Section 5), but in fact, it is the IKK
complex, not the NF-κB system, which is a potent inducer of autop-
hagy [199,200] probably enhancing autophagocytosis if there is a
genotoxic stress and during the appearance of senescent phenotype.
Narita et al. [201] described a cellular compartment called TASCC, a
TOR-autophagy spatial coupling compartment, where mTOR became
accumulated into autolysosomes during RAS-induced senescence.
TASCC combines two basic cellular activities, protein synthesis gov-
erned by mTOR and degradation driven by autophagy. Interestingly,
they demonstrated that secretory IL-6 and IL-8 were enriched in
TASCC in secretory senescent cells and could be involved in the ap-
pearance of SASP. Moreover, IKKβ is a potent activator of mTOR by
inhibiting TSC1 [202] and thus the signaling pathways activating
IKKβ after genotoxic stress, e.g. ATM-stimulated complexes, could
trigger SASP via TASCC activation. It is possible that in acute cellular
stress, the role of IKK-dependent, NF-κB-independent signaling is
augmented since stress triggers the expression of two heat shock pro-
teins, Hsp70 and Hsp90, which dissociate the IKK complexes and pre-
vent the activation of the NF-κB system but not that of IKKs. We have
recently reviewed this topic [203]. In conclusion, it seems that the IKK
complex is an important player in the regulation of cellular senes-
cence, in particular in the induction of SASP.
7. Conclusions
Emerging studies indicate that the NF-κB signaling pathway con-
trols the generation of cellular phenotype called SASP, i.e. the secre-
tion of inﬂammatory factors, e.g. cytokines and chemokines,
increases in senescent cells. Cellular senescence is generally induced
by genotoxic injuries which arrest the cell cycle of damaged cells
and thus prevent their conversion into cancerous cells. For instance,
843A. Salminen et al. / Cellular Signalling 24 (2012) 835–845oxidative stress associated with inﬂammation can jeopardize DNA in-
tegrity, in particular with aging and diseases, and activate the senes-
cence program in proliferating cells. Several studies have revealed
that the number of senescent cells increases in the tissues of old ani-
mals as well as in many diseases. In cancer, this state has been called
OIS, oncogene-induced senescence. Recent studies have clearly indi-
cated that SASP is not required for the generation of cellular senes-
cence and it seems that secretory component is only a common
characteristic of senescent phenotype. Most of secreted compounds
are linked to inﬂammation and they can have both beneﬁcial and det-
rimental effects [204]. Many of the pro-inﬂammatory factors are
alarm-issuing molecules which recruit monocytes and macrophages
into tissues to assure local homeostasis. In addition, secreted mole-
cules can arrest the proliferation of neighboring cells and thus func-
tion as growth suppressors, e.g. in tumors, but autonomously, also
to maintain their own arrested, secretory phenotype. Activation of
the innate immunity system and the presence of a low-grade inﬂam-
mation are general characteristics of organismal aging [29]. The aging
process is also associated with a clear activation of the NF-κB system
in many tissues [205,206]. However, it needs to be clariﬁed whether
cellular senescence is involved in this activation or whether genotoxic
injuries appearing in conjunction with aging stimulate a secretory
phenotype also in non-senescent cells.
Studies on cellular senescence have revealed that genotoxic stress,
particularly DNA damage, and the activation of ATM, a DNA damage-
inducible kinase, can trigger the activation of the NF-κB system via
several signaling pathways, i.e. NEMO shuttle as well as p38MAPK
and RIG-1 pathways (Fig. 1). The age-related increase in ceramides
is also a potent inducer of NF-κB signaling. It seems that epigenetic
changes, both in cellular senescence and organismal aging, can en-
hance the transcription of NF-κB-dependent inﬂammatory genes,
e.g. via changes in HMGB1 and SIRT6 function. On the other hand,
the NF-κB system is strictly regulated, e.g. via negative feedback
loops, and its efﬁciency oscillates with other transcription factors.
The NF-κB system is an ancient defense mechanism which has a cru-
cial role in morphogenesis and the survival of the organism but later
in life, an inappropriate immune defense could have detrimental ef-
fects. This phenomenon refers to antagonistic pleiotropy, a well-
known hypothesis to account for the aging process.
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